var data={"title":"Sodium iodide I-131: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium iodide I-131: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/147201?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-iodide-i-131-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium iodide I-131: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521692\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hicon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521696\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antithyroid Agent;</li>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2522218\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If dose or dose within range exceeds 1,000 microcuries, dose will be expressed as <b>milli</b>curies. Adhere to radiation safety precautions regarding radioactive iodine treatment. Discontinue antithyroid medications 3 to 4 days prior to administration of sodium iodide I131.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic procedures:</b> Oral (based on a 70 kg patient): <b>Note:</b> Consult manufacturer potency tables when applicable. All doses should be individualized; general ranges are listed here:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thyroid uptake: 5 to 30 microcuries (or 0.185 to 1.1 megabecquerels) 24 hours prior to uptake measurement; alternatively, a maximum dose of 10 microcuries (0.37 megabecquerels) has been recommended (ACR-SPR 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment if used in conjunction with technetium Tc 99m sodium pertechnetate:</i> 4 to 5 microcuries (0.15 to 0.185 megabecquerels) (ACR-SPR 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thyroid imaging: 50 to 100 microcuries (or 1.85 to 3.7 megabecquerels) 16 to 24 hours prior to imaging. <b>Note:</b> Alternative agents (eg, sodium iodide I<sup>123</sup>, technetium-99m pertechnetate) are recommended for routine thyroid scintigraphy due to increased thyroid radiation exposure with sodium iodide I<sup>131</sup> (ACR-SPR 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Whole-body imaging for thyroid cancer metastases (off-label): 1 to 5 <b>milli</b>curies (37 to 185 megabecquerels) 24 to 72 hours prior to imaging (ACR-SPR 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment:</b> Individual dose based on thyroid uptake and gland size. Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Hyperthyroidism:</b></i> Manufacturer&rsquo;s labeling recommends 4 to 10 <b>milli</b>curies (or 148 to 370 megabecquerels); however, due to high failure rates, RAI therapy with low activities is generally not recommended (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Graves&rsquo; disease (off-label dosing):</i> 10 to 15 <b>milli</b>curies (or 370 to 555 megabecquerels) <b>or</b> 150 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation below) (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Toxic multinodular goiter (off-label dosing):</i> 150 to 200 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation below); if hyperthyroidism persists, may repeat after 6 months if needed (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Toxic thyroid adenoma (off-label dosing):</i> 10 to 20 <b>milli</b>curies (or 370 to 740 megabecquerels) <b>or </b>150 to 200 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation below); if hyperthyroidism persists, may repeat after 6 months if needed (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose equation corrected for 24-hour radioactive iodine uptake: Activity (<b>milli</b>curies) = (gland weight in grams x desired dose in microcuries/gram x [1/24 hour uptake in % of dose])/1,000 (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Thyroid cancer:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ablation of normal thyroid tissue: Initial: 30 to 100 <b>milli</b>curies (or 1,100 to 3,700 megabecquerels). <b>Note:</b> If remnant ablation is performed after total thyroidectomy for American Thyroid Association (ATA) low-risk thyroid cancer or intermediate-risk disease with lower risk features, a low administered activity of ~30 <b>milli</b>curies is generally favored over higher administered activities. For initial adjuvant therapy when microscopic residual disease is suspected (in the absence of known distant metastases), up to 150 <b>milli</b>curies has been recommended (Haugen 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Subsequent metastases ablation: 100 to 200 <b>milli</b>curies (or 3,700 to 7,400 megabecquerels)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13317074\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Graves disease (off-label use):</b> Children &ge;5 years of age: Oral: Dose is dependent upon gland size; &gt;150 microcuries/g of thyroid tissue is necessary to induce hypothyroidism; if gland is between 50 to 80 g, higher activities (200 to 300 microcuries/g of thyroid tissue) may be needed. Therapy in children between 5 to 10 years of age is acceptable if the calculated dose is &lt;10 <b>milli</b>curies (Ross 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2522219\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Empiric dosing for subsequent pulmonary micrometastases ablation for patients &ge;70 years: 100 to 150 <b>milli</b>curies (Haugen 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22558280\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in manufacturer's labeling. However, patients with renal impairment may have decreased clearance and increased radiation exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Sodium iodide I<sup>131</sup> is dialyzable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22558281\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2522262\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule [diagnostic]: 0.555 megabecquerels [15 microcuries]; 0.925 megabecquerels [25 microcuries]; 1.85 megabecquerels [50 microcuries]; 3.7 megabecquerels [100 microcuries]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule [therapeutic]: 28-3700 megabecquerels [0.75-100 millicuries]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iodotope: 37-4810 megabecquerels [1-130 millicuries]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit [therapeutic]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hicon 9.25 gigabecquerels (250 millicuries):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Dibasic sodium phosphate 300 mg (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Empty large gelatin capsule (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Sodium iodide I<sup>131</sup> 9.25 gigabecquerels (250 millicuries) per 0.25 mL (0.25 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hicon 18.5 gigabecquerels (250 millicuries):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Dibasic sodium phosphate 300 mg (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Empty large gelatin capsule (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Sodium iodide I<sup>131</sup> 18.5 gigabecquerels (500 millicuries) per 0.5 mL (0.5 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hicon 37 gigabecquerels (1000 millicuries):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Dibasic sodium phosphate 300 mg (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Empty large gelatin capsule (10s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Sodium iodide I<sup>131</sup> 37 gigabecquerels (1000 millicuries) per 1 mL (1 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution [therapeutic]: 129.5-5550 megabecquerels per vial [3.5-150 millicuries per vial; contains sodium bisulfite and edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521694\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2522220\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ensure adequate hydration before and after treatment; instruct patients to void frequently to enhance elimination of radioiodide not absorbed by thyroid. Adhere to radiation safety precautions regarding radioactive iodine treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Hicon: Administer on an empty stomach; patient should fast at least 2 hours before and 2 hours after administration to ensure adequate absorption. Solution must be diluted and prepared prior to administration; do not administer concentrated solution. Provide solution dose in a shielded container with a straw for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn while handling and administering sodium iodide I<sup>131</sup>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521699\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic agent:</b> Diagnostic use in performance of radioactive iodide (RAI) uptake test to evaluate thyroid function and for thyroid imaging. <b>Note:</b> Alternative agents (eg, sodium iodide I<sup>123</sup>, technetium-99m pertechnetate) are recommended for routine thyroid scintigraphy due to increased thyroid radiation exposure with sodium iodide I<sup>131</sup> (ACR-SPR 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Therapeutic agent:</b> Treatment of hyperthyroidism and select cases of thyroid carcinomas (if the lesions take up iodide); palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50587753\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Whole body imaging for thyroid cancer metastases</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15245847\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521720\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined, dose dependent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebral edema (in patients with iodine-avid brain metastases), metallic taste</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, pruritus, skin lesion (iododerma), skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperthyroidism, hypoparathyroidism, hypothyroidism, thyroiditis, thyroid storm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastritis, nausea (high dose used in treatment of thyroid cancer), odynophagia, salivary gland disease, sialadenitis, sore throat, unpleasant taste, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Infertility (transient; may be permanent in males with repeated or high dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Acute leukemia, anemia, bone marrow depression (high dose used in treatment of thyroid cancer), hematologic abnormality, leukopenia, solid tumor, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Neck discomfort (tenderness/swelling)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cough, pulmonary fibrosis (in patients with iodine-avid lung metastases), radiation pneumonitis (in patients with iodine-avid lung metastases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Chromosomal abnormality, local swelling, radiation injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Conjunctivitis, epiphora, neoplasm (rare; causative role not established), xerophthalmia, xerostomia (high dose used in treatment of thyroid cancer)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521705\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Preexisting vomiting and diarrhea (treatment); concurrent antithyroid medication (discontinue 3 to 4 days prior to administration); women who are or may become pregnant; breastfeeding; treatment of thyroid malignancies shown to have no iodide uptake, which include the majority of medullary and anaplastic carcinomas</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521706\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including rash and hives) have been reported following sodium iodide I<sup>131</sup> administration. Sodium iodide I<sup>131</sup> solution may contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes. The overall incidence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. During pretherapy assessment, question patients about a history of hypersensitivity to sulfite.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infertility: Transient, dose-related testicular function impairment after sodium iodide I<sup>131</sup> use; consider sperm banking for men who are anticipated to receive a high cumulative dose (eg, &gt;14 GBq). Transient ovarian failure has been observed in females after sodium iodide I<sup>131</sup> treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation-induced thyroiditis: Sodium iodide I<sup>131</sup> may cause thyroiditis (with gland enlargement) and thyroid hormone release, particularly if used in the treatment of hyperthyroidism. Thyroiditis may cause or worsen hyperthyroidism, and may lead to thyroid storm. When treating hyperthyroidism, consider pretreatment with antithyroid medication to help deplete thyroid hormone content within the gland. Discontinue antithyroid medication at least 3 days prior to sodium iodide I<sup>131</sup> administration. Consider beta-blocker therapy prior to sodium iodide I<sup>131</sup> administration to minimize the risk of hyperthyroidism and thyroid storm. Thyroiditis may result in gland enlargement with neck tenderness and swelling, pain with swallowing, sore throat, and cough; may require management with anti-inflammatory medications or analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation toxicities: Radiation-induced toxicities, including dose-dependent fatalities, have been reported following sodium iodide I<sup>131</sup> therapy. Postmarketing reports have identified an increased risk for neoplasia, as well as a risk of hematopoietic suppression (transient neutropenia/thrombocytopenia; onset 3 to 5 weeks). Salivary and lacrimal gland toxicity is relatively common and may manifest as conjunctivitis, xerophthalmia, epiphora, sialadenitis, and xerostomia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid-stimulating hormone/thyroid enlargement: Enhanced thyroid-stimulating hormone (TSH) secretion (eg, following discontinuation of antithyroid medications, or the administration of TSH to enhance sodium iodide I<sup>131</sup> uptake) may cause thyroid enlargement and obstructive complications of the trachea, esophagus, or blood vessels in the neck. Evaluate patients at high risk of obstructive complications prior to preparative treatments known to cause thyroid enlargement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism/thyrotoxic cardiac disease: May be aggravated by radiation thyroiditis; consider pre- and post-treatment with antithyroid agents and/or beta-blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypochloremia: May increase thyroid uptake of sodium iodide I<sup>131</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Sodium iodide I<sup>131</sup> is eliminated predominantly renally; patients with renal impairment may have decreased clearance and increased radiation exposure. Sodium iodide I<sup>131</sup> is dialyzable and hemodialysis may be used to decrease total body radiation exposure. Evaluate renal function prior to treatment. Nephrosis may increase thyroid uptake of sodium iodide I<sup>131</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iodine/thyroid medications: Concomitant use of iodine, thyroid, or antithyroid medications may interfere with the uptake of radioiodide; medications should be discontinued for an appropriate time prior to dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are more likely to have decreased renal function and comorbid conditions; may require close evaluation, dose selection, and follow-up compared with younger patients. When treating hyperthyroidism in geriatric patients at risk of developing cardiac complications, pre- and post-treatment with antithyroid drugs and/or beta-blockers may minimize the risk of excessive post-treatment hyperthyroidism due to radiation-induced thyroiditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: The thyroid gland may be more sensitive to the effects of sodium iodide I<sup>131</sup> in pediatric patients; safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. Unwanted radiation exposure can occur from handling and administration of radiopharmaceuticals or from contaminated waste products, including urine and feces. Patients must be instructed in measures to minimize exposure of others.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients should be adequately hydrated prior to and for at least 1 week following administration. Frequent voiding is recommended to enhance radioiodide excretion. Stimulate salivary flow (gum or sugar-free candy) to reduce radiation exposure to salivary glands. Avoid close contact with others (especially pregnant women and children) and contamination of other persons or the environment with body fluids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300058\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223000\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10276&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Sodium Iodide I131.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May diminish the therapeutic effect of Sodium Iodide I131. Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May diminish the therapeutic effect of Sodium Iodide I131.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521700\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521701\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in pregnancy. Iodine-131 crosses the placenta and may cause severe and irreversible hypothyroidism in neonates. Pregnancy should be ruled out prior to therapy. Use of 2 effective methods of contraception is recommended (for females and males) during treatment and for at least 12 months following administration; if additional iodide I<sup>131</sup> therapy or radionuclide imaging is anticipated, the use of 2 effective methods of contraception may be necessary for at least 1 year. Elective diagnostic procedures should be delayed until after delivery (Parker 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521704\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use is contraindicated in breastfeeding. Iodine-131 is excreted in breast milk and concentrations may be equal to or greater than maternal plasma concentrations. To minimize radiation absorbed into the breast tissue, the manufacturer recommends that breastfeeding and pumping be discontinued at least 4 weeks prior to sodium iodide I<sup>131</sup> administration. If sodium iodide I<sup>131</sup> is administered during the postpartum period, the lactating mother should not breastfeed the infant; breastfeeding may be resumed with the birth of another child (if no sodium iodide I<sup>131</sup> is administered in that postpartum period).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elective diagnostic procedures should be delayed until breastfeeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521728\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer recommends maintaining a low iodide diet two weeks before administration and to continue for several days during the uptake and imaging process.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In the treatment of Graves disease, it has been recommended that a special diet prior to RAI therapy is not required, but nutritional supplements containing excess iodine and seaweeds be avoided for at least 7 days; a low-iodine diet may benefit those with relatively low RAI uptake to increase the proportion of RAI trapped (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate, and iodized salt.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24247090\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Thyroid function tests (TSH, free T<sub>4</sub>, total T<sub>3</sub>) within 1 to 2 months post-treatment and at 4 to 6 week intervals for 6 months, or until hypothyroid and stable on thyroid hormone replacement (Graves disease, toxic multinodular goiter, toxic adenoma) (Ross 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24247088\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oral sodium iodide I<sup>131</sup> is rapidly absorbed and distributed within the extracellular fluid of the body. Iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. Beta emission of sodium iodide I<sup>131</sup> destroys thyroid tissue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2522212\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapidly (90% within 60 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Extracellular space; primarily trapped by the thyroid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Iodide is rapidly oxidized to iodine in the thyroid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (37% to 75%); feces ~10%</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      American College of Radiology (ACR) and Society for Pediatric Radiology (SPR). ACR&ndash;SPR practice parameter for the performance of scintigraphy and uptake measurements for benign and malignant thyroid disease. 2014. https://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/Thyroid_Scintigraphy.pdf. Accessed August 3, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26462967\"></a>Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-iodide-i-131-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hicon (sodium iodide I 131 solution - therapeutic) [prescribing information]. Kirkland, Quebec, Canada: Jubilant Draximage Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meier DA, Brill DR, Becker DV, et al, &ldquo;Procedure Guideline for Therapy of Thyroid Disease With (131)Iodine,&rdquo; <i>J Nucl Med</i>, 2002, 43(6):856-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-iodide-i-131-drug-information/abstract-text/12050333/pubmed\" target=\"_blank\" id=\"12050333\">12050333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al. Procedure Guideline for General Imaging: 3.0. Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27521067\"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi: 10.1089/thy.2016.0229<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-iodide-i-131-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium iodide I 131 solution - diagnostic [prescribing information]. Kirkland, Quebec, Canada: Jubilant Draximage Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium iodide I 131 solution - therapeutic [prescribing information]. St. Louis, MO: Mallinckrodt Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium iodide I 131 capsules - therapeutic [prescribing information]. St. Louis, MO: Mallinckrodt Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials. 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10276 Version 71.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2521692\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2521696\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2522218\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13317074\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2522219\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22558280\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22558281\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2522262\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2521694\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2522220\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2521699\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50587753\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15245847\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2521720\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2521705\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2521706\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300058\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223000\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2521700\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2521701\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2521704\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2521728\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24247090\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24247088\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2522212\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10276|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-iodide-i-131-patient-drug-information\" class=\"drug drug_patient\">Sodium iodide I-131: Patient drug information</a></li></ul></div></div>","javascript":null}